News

New Chief Commercial Officer Joins Hemanext Team to Drive Execution

Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, is pleased to welcome Mr. Shane Ray to the team as Chief Commercial Officer (CCO). In this role, Shane will lead the global commercial strategy and execution for Hemanext ONE®.

With over 20 years of global leadership experience in the med-tech industry, Shane brings a proven track record in commercialization, strategic marketing and business development for high-growth medical device companies. Previously, Shane held the position of North American President and Global Chief Marketing Officer at curasan, Inc, a global tech company focused on regenerative medicine, primarily in bone replacement materials. He also held senior leadership roles at RTI Surgical and Pioneer Surgical Technology, directing sales and marketing initiatives across orthobiologics, sports medicine, and the spinal therapeutic area, among others.

Andrew Dunham, CEO of Hemanext stated, “We are thrilled to welcome Shane Ray as our new Chief Commercial Officer. His proven leadership and strategic vision will be pivotal as we accelerate our commercial growth and deepen our customer impact.”

“I am honored and thrilled to join the Hemanext team”, said Shane Ray, CCO of Hemanext. “Hemanext is pioneering innovative blood therapies, and I look forward to building on the company’s strong foundation to advance patient outcomes while driving sustainable commercial success”.

About Hemanext

Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company’s research and development efforts focus on the study of hypoxically stored red blood cells (RBCs). The company’s aim is to significantly improve the quality of stored RBCs worldwide.

About Hemanext ONE

HEMANEXT ONE is a first in class device to improve the quality of RBCs for transfusion dependent patients. HEMANEXT ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration further exhibiting the product’s innovation and commercial impact. In Europe, HEMANEXT ONE is CE marked, allowing commercial distribution within the market of the European Economic Area (EEA).

Hemanext Media Contact
Robert Haime
Vice President, Commercial
robert.haime@hemanext.com
(781) 301-7474

Previous
Next

By producing higher quality RBCs, the Hemanext ONE system has the potential to enable fewer and more effective transfusions for patients. I am truly excited by the possibility of bringing this improved red blood cell replacement therapy to populations in the U.S. that have been waiting for a transformative technology like this one.

Dr. Philip C. Spinella
Professor, Department of Surgery and Department of Critical Care Medicine at University of Pittsburgh

We value our partnership with Hemanext to enhance blood product quality and availability. Hemanext ONE has the potential to strengthen the resiliency of the blood supply, and this FDA authorization is a significant milestone to that end.

Ralph Vassallo, MD, FACP
Executive Vice President, Chief Medical and Scientific Officer of Vitalant

The Hemanext ONE system offers promise to improve the treatment landscape for patients burdened by transfusions and could be an essential step towards performing fewer and better transfusions. Having long championed Hemanext’s transformative initiatives, I eagerly anticipate witnessing the positive influence, right here in the United States, on the advancement of transfusion therapy quality.

Paul M. Ness, MD
Former Director, Division of Transfusion Medicine at Johns Hopkins University and board member of Hemanext

By deoxygenating red cells and maintaining them in their hypoxic state throughout storage, the resulting red cells experience less oxidative stress and oxidative damage, have improved metabolism, and are also more deformable leading to improved micro vascular profusion and less hemolysis.

Dr. Steven Spitalnik, MD
Co-Director of the Laboratory of Transfusion Biology, Colombia University

The preclinical data by Williams et al. show anaerobically stored RBCs achieve multiple clinically important functional resuscitation goals, with a smaller volume of fluid and the FDA benchmark of 24-hour RBC recovery. I look forward to the clinical trials in bleeding patients.

John Holcomb, MD, FACS
University of Alabama at Birmingham

I have had several patients who have received Hemanext hypoxic blood, and several of the patients have personally said thanks for having been given the opportunity and also that they have felt better after transfusion with hypoxic blood compared to conventional transfusion. One must of course be careful not to attach too much importance to such observations, but I would still like to mention that there has been a remarkable tendency towards this.

Håkon Reikvam, MD, PhD
Professor, Department of Clinical Science, University of Bergen, Norway

CONTACT US  |  TERMS OF USE

PRIVACY & COOKIES POLICY

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2026 Hemanext, Inc. All rights reserved.

Contact Us